Last reviewed · How we verify
Placebo of NICOTINE Transdermal patch — Competitive Intelligence Brief
phase 3
Addiction Medicine / Smoking Cessation
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo of NICOTINE Transdermal patch (Placebo of NICOTINE Transdermal patch) — Assistance Publique - Hôpitaux de Paris. This is a placebo control formulation containing no active nicotine, used as a comparator in clinical trials to assess the true efficacy of nicotine transdermal patches.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo of NICOTINE Transdermal patch TARGET | Placebo of NICOTINE Transdermal patch | Assistance Publique - Hôpitaux de Paris | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo of NICOTINE Transdermal patch CI watch — RSS
- Placebo of NICOTINE Transdermal patch CI watch — Atom
- Placebo of NICOTINE Transdermal patch CI watch — JSON
- Placebo of NICOTINE Transdermal patch alone — RSS
Cite this brief
Drug Landscape (2026). Placebo of NICOTINE Transdermal patch — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-of-nicotine-transdermal-patch. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab